GSK.L Stock Analysis
GS
Neutral
Based on Eyestock quantitative analysis, GSK.L`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly undervalued
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. The company is headquartered in Brentford, Middlesex and currently employs 69,400 full-time employees. The firm makes vaccines and specialty medicines to prevent and treat disease. Its segments include Commercial Operations and Research and Development. The company develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. The company has developed a new monoclonal antibody treatment for COVID-19. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions, including the chronic autoimmune condition lupus, respiratory disease, and human immunodeficiency virus (HIV). Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics and medicines for skin diseases. The company has a global network of about 12 vaccines manufacturing sites.